Show simple item record

dc.contributor.authorKrug, Sebastian J
dc.contributor.authorHu, Qingzhong
dc.contributor.authorHartmann, Rolf W
dc.date.accessioned2013-08-14T14:20:01Z
dc.date.available2013-08-14T14:20:01Z
dc.date.issued2013-03
dc.identifier.citationHits identified in library screening demonstrate selective CYP17A1 lyase inhibition. 2013, 134:75-9 J. Steroid Biochem. Mol. Biol.en_GB
dc.identifier.issn1879-1220
dc.identifier.pmid23142656
dc.identifier.doi10.1016/j.jsbmb.2012.10.019
dc.identifier.urihttp://hdl.handle.net/10033/298252
dc.description.abstractA screening of structurally different steroid hormone synthesis inhibitors was performed in order to find a starting point for the development of a new inhibitor of the bifunctional steroidogenic enzyme CYP17A1. Emphasis was placed on determination of selectivity between the two catalytic steps, namely 17α-hydroxylase and C(17,20)-lyase. For that purpose a new inhibition assay has been developed. Hits identified within this novel assay demonstrated selective inhibition of CYP17A1 lyase activity, and thus mark the basis for the development of selective C(17,20)-lyase inhibitors for the treatment of prostate cancer.
dc.language.isoenen
dc.rightsArchived with thanks to The Journal of steroid biochemistry and molecular biologyen_GB
dc.subject.meshEnzyme Inhibitorsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshInhibitory Concentration 50en_GB
dc.subject.meshMaleen_GB
dc.subject.meshProstatic Neoplasmsen_GB
dc.subject.meshSmall Molecule Librariesen_GB
dc.subject.meshSteroid 17-alpha-Hydroxylaseen_GB
dc.titleHits identified in library screening demonstrate selective CYP17A1 lyase inhibition.en
dc.typeArticleen
dc.contributor.departmentPharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany.en_GB
dc.identifier.journalThe Journal of steroid biochemistry and molecular biologyen_GB
refterms.dateFOA2018-06-12T23:39:19Z
html.description.abstractA screening of structurally different steroid hormone synthesis inhibitors was performed in order to find a starting point for the development of a new inhibitor of the bifunctional steroidogenic enzyme CYP17A1. Emphasis was placed on determination of selectivity between the two catalytic steps, namely 17α-hydroxylase and C(17,20)-lyase. For that purpose a new inhibition assay has been developed. Hits identified within this novel assay demonstrated selective inhibition of CYP17A1 lyase activity, and thus mark the basis for the development of selective C(17,20)-lyase inhibitors for the treatment of prostate cancer.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Krug, Hu and Hartmann_final.pdf
Size:
319.9Kb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record